A biopharmaceutical firm specializing in rare and ultra-rare disease research started working with Veristat over 7 years ago.
Case Study
Imagine you are getting ready to launch the third drug cohort of your early phase clinical trial for a pancreatic cancer vaccine study and your in-house lead CRA overseeing your sites in Europe retires. This happened to our client, who brought on Veristat to transition and seamlessly continue monitoring for the sites in this cohort.
Case Study
A clinical-stage biopharmaceutical company came to Veristat with a complex statistical methodology for running a phase II adaptive design trial with the goal of expediting a go/no-go decision for a specific patient population.
Case Study
We are more than just your typical boutique "CRO" that caters to growing firms. Meet us and consider why you should speak with Veristat for the design and implementation of your clinical trials and regulatory submissions.
Case Study
A mid-size pharmaceutical company and its development partner, a small biotechnology company engaged Veristat to complete the medical writing for their product’s Marketing Authorization Application (MAA), New Drug Application (NDA), and New Drug Submission (NDS).
Case Study
